PURPOSE: The present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L L-proline (Privigen), in patients with primary immunodeficiency disease. MATERIALS AND METHODS: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. RESULTS: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg(-1) min(-1)). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9% of infusions, either during or within 72 h after infusion end. CONCLUSION: Privigen is well tolerated and effective for the treatment of primary immunodeficiency.
PURPOSE: The present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous immunoglobulin, stabilized with 250 mmol/L L-proline (Privigen), in patients with primary immunodeficiency disease. MATERIALS AND METHODS: Eighty adults and children diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen infusions (200-888 mg/kg) at 3- or 4-week intervals over a 12-month period, according to their previously established maintenance dose. The primary endpoint was the annual rate of acute serious bacterial infections. RESULTS: There were six episodes of acute serious bacterial infections, corresponding to an annual rate of 0.08; the annual rate for all infections was 3.55. Mean serum IgG trough levels were between 8.84 and 10.27 g/L. A total of 1,038 infusions were administered, most of them at the maximum rate permitted (8.0 mg kg(-1) min(-1)). Temporally associated adverse events, possibly or probably related to study drug, occurred in 9% of infusions, either during or within 72 h after infusion end. CONCLUSION: Privigen is well tolerated and effective for the treatment of primary immunodeficiency.
Authors: H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens Journal: Ann Intern Med Date: 2001-08-07 Impact factor: 25.391
Authors: C Cunningham-Rundles; F P Siegal; E M Smithwick; A Lion-Boulé; S Cunningham-Rundles; J O'Malley; S Barandun; R A Good Journal: Ann Intern Med Date: 1984-10 Impact factor: 25.391
Authors: J N Moy; A M Scharenberg; M R Stein; D Suez; R L Roberts; R J Levy; M Ballow; M B Fasano; C H Dash; S J Leach Journal: Clin Exp Immunol Date: 2010-12 Impact factor: 4.330
Authors: Richard L Wasserman; Isaac Melamed; Lisa Kobrynski; Steven D Strausbaugh; Mark R Stein; Marlies Sharkhawy; Werner Engl; Heinz Leibl; Luba Sobolevsky; David Gelmont; Richard I Schiff; William J Grossman Journal: J Clin Immunol Date: 2011-03-22 Impact factor: 8.317
Authors: H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman Journal: Clin Exp Immunol Date: 2015-07-07 Impact factor: 4.330
Authors: M Ballow; L Notarangelo; B Grimbacher; C Cunningham-Rundles; M Stein; M Helbert; B Gathmann; G Kindle; A K Knight; H D Ochs; K Sullivan; J L Franco Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330
Authors: John B Hagan; Mary B Fasano; Sheldon Spector; Richard L Wasserman; Isaac Melamed; Mikhail A Rojavin; Othmar Zenker; Jordan S Orange Journal: J Clin Immunol Date: 2010-05-08 Impact factor: 8.317